Page 11 - Aging Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

pandemic, and now as vaccines become more widely available, we are reporting on how our local schools, businesses and communities are returning to a more "normal" future. There's never been more of a need for the kind of local, independent and unbiased journalism that The Day produces. Please support our work by subscribing today. Alzheimer's drug sparks emotional battle as FDA nears deadline on whether to approve A mental fog descended when Phil Gutis was diagnosed with Alzheimer's. An experimental drug, he says, helped dissipate that fog, but now access to the medication could be imperil...

Biogen is seeking FDA approval this week for a new drug that may be able to slow down the cognitive decline cause by Alzheimer's. Some oppose the approval, saying the drug doesn't work.

By June 7, the FDA is expected to make one of its most important decisions in years: whether to approve a drug for mild cognitive impairment or early-stage dementia caused by Alzheimer's disease.

The drug aducanumab would be the first new Alzheimer’s treatment since 2003, but it is also the latest example of a controversial medication that is passionately supported by patients and advocacy groups but has been rejected by the FDA’s outside advisers.

Brown University President Christina Paxson Brown University announced Wednesday that it is establishing a new Center for Alzheimer’s Disease Research with the aim of building a world-class research program focused on early detection and treatment of Alzheimer's disease and related dementias. The center will integrate the expertise of scientists and physicians at Brown’s Robert J. and Nancy D. Carney Institute for Brain Science and the Division of Biology and Medicine, home to the Warren Alpert Medical School. Its launch is made possible by gifts of $25 million and $5 million from donors ...